BNET Industries

Celera Genomics Group

(CRA) is in the Business Services Industry

Market Cap:$515.4M
Last Fiscal Year Sales:$60.1M
  • Public
  • US
Dow Jones Description

Like the genome, Celera has its future all mapped out. Founded in 1998 and headquartered in Rockville, MD, Celera Genomics Group (NYSE: CRA) discovers and develops therapeutics for cancer, autoimmune, and inflammatory diseases. The company sequenced the human genome and licenses its database, through sister company Applied Biosystems, to third party biotech and drug firms. It also has a focus on proteins and protein-based therapeutics. It has partnerships with Genentech, Abbott Labs, and other firms. It is a part of Applera Corporation. The company had 2005 revenue of about $31.1 million and employs about 480 people. In June 2006, it sold its cathespin S inhibitor small molecule drug program to Schering AG for about $5 million.

Number of Employees 530
Contact Information

45 W Gude Dr

Rockville, Maryland 20850-1159

www.celera.com

(240) 453-3000

NAICS Code Research and Development in the Social Sciences and Humanities: 541720

News & Analysis

celera genomics group - All News and Analysis

Decision Makers

Name (plus bio) Position
Kathy P. Ordonez President
Paulette Dillon Chief Business Officer
Samuel E. Broder Chief Medical Officer
Stacey Sias Chief Business Officer
Tom White Chief Scientific Officer & Vice President, Res & Development
Victor K. Lee Vice President & Chief Group Counsel
Diane Wolfe Vice President, Manufacturing
James Yee Vice President, Development
Joel Jung Vice President, Finance
John Sninsky Vice President, Discovery Res
Michael J. Green Vice President, Chemistry
Mike Zoccoli Vice President, Development
Peter R. Young Vice President, Biology
Steven Ruben Vice President, Protein Therapeutics
David P. Speechly Senior Director, Investor Relations & Communications
Eric Shulse Marketing Director
Raymond Cyrus Director, Internet Strategies

Organization Position Status
Applied Biosystems Group President Current
Celera Genomics Group President Current
Applera Corporation Senior Vice President Current
Celera Genomics Senior Vice President, Applera and President, Celera Genomics and Celera Diagnostics Current
Celera Genomics CEO and Director Current
Roche Molecular Systems, Inc. Chief Executive Officer Former
Applera Corporation Chief Executive Officer Former
Celera Genomics President Former
Applera Corporation President Former
Hoffmann-La Roche Inc. President Former
Roche Molecular Systems, Inc. President Former
Celera Genomics President Former
Celera Diagnostics, LLC President Former
Applied Biosystems Group Senior Vice President, Applera Corporation, President, Celera Genomics and Celera Diagnostics Former
Union Carbide Corporation Former
Roche Former
Applera Corporation Chairman Former
Hartwick College Bachelor's Degree In Chemistry Former

Organization Position Status
Celera Genomics Group Chief Business Officer Current

Samuel Broder, M.D., joined Celera in 1998 and presently serves as Chief Medical Officer. He is a physician-scientist with special expertise in the relationship between disorders of the immune system and cancer. Dr. Broder began his research career in the Metabolism Branch of the National Cancer Institute (NCI) in 1972. Following the onset of the AIDS epidemic, Dr. Broder’s laboratory added studies of anti-retroviral agents to its research repertoire and made significant contributions to the development of AIDS drugs such as AZT ddl and ddC. In 1989, President Ronald Reagan named Dr. Broder Director of the NCI. Under his leadership, the NCI initiated a number of important large-scale human trials in the prevention, diagnosis, and treatment of cancer. In the spring of 1995, Dr. Broder became Senior Vice President for Research and Development at the IVAX Corporation in Florida, where he directed a broad range of pharmaceutical research on new drugs for heart disease, diabetes and diseases of the lung. Dr. Broder received his bachelor’s and M.D. degrees from the University of Michigan. He is a member of the Institute of Medicine of the U.S. National Academy of Sciences, is the author of more than 300 scholarly papers, and holds numerous patents.

Organization Position Status
Celera Genomics Group Chief Medical Officer Current

Stacey is the Chief Business Officer of Celera. She holds a B.S. from Simmons College and a Ph.D. in Bacteriology from the University of California at Davis. Stacey is also a registered Patent Agent with the U.S. Patent and Trademark Office. Prior to joining Celera Diagnostics, she was the Vice President of Licensing at Roche Molecular Systems and held various positions within the Hoffmann La-Roche law department supporting their molecular diagnostic activities. Her experience includes activities as a patent agent at Cetus Corporation and as a molecular biologist at Codon and Genentech.

Organization Position Status
Celera Genomics Group Chief Business Officer Current

Tom White is the Chief Scientific Officer and Vice President of Research for Celera. He received his B.A. in Chemistry from Johns Hopkins University and his Ph.D. in Biochemistry from the University of California at Berkeley. His postdoctoral research was carried out at the University of California Medical Center in San Francisco and at the University of Wisconsin at Madison. From 1978 to 1989, Tom held various positions at Cetus Corporation including Vice President of Research and Associate Director of Research and Development . From 1989-2000 he worked for Roche Molecular Systems as Sr. Vice President of Research and Development.

Organization Position Status
Celera Genomics Group Chief Scientific Officer & Vice President, Res & Development Current

Organization Position Status
Celera Genomics Group Vice President & Chief Group Counsel Current

Organization Position Status
Celera Genomics Group Vice President, Manufacturing Current

Organization Position Status
Celera Genomics Group Vice President, Development Current

Organization Position Status
Celera Genomics Group Vice President, Finance Current
Applera Corporation Assistant Controller Current

Organization Position Status
Celera Genomics Group Vice President, Discovery Res Current

Organization Position Status
Celera Genomics Group Vice President, Chemistry Current

Mike Zoccoli is the General Manager of the Products Business. He earned a B.A. in Chemistry at the University of Connecticut and a Ph.D. in Chemistry from Dartmouth College. After post-doctoral studies at Harvard Medical School supported by fellowships from the National Institutes of Health and the Juvenile Diabetes Foundation, he started his career in the diagnostics industry at Syva Company in 1982. He has worked throughout his career in product development and project management at a number of companies including Cetus, Roche Molecular Systems, Applied Imaging Corporation, and Bayer Diagnostics.

Organization Position Status
Celera Genomics Group Vice President, Development Current

Organization Position Status
Celera Genomics Group Vice President, Biology Current

Organization Position Status
Celera Genomics Group Vice President, Protein Therapeutics Current

Organization Position Status
Celera Genomics Group Senior Director, Investor Relations & Communications Current

Organization Position Status
Celera Genomics Group Marketing Director Current

Organization Position Status
Celera Genomics Group Director, Internet Strategies Current
advertisement
     CRA $6.29 +0.04 (0.64% )
Intraday | 3 Month | 6 Month | 1 Year
Average Volume 712,414
Shares Outstanding 81.94M
Market Cap 515.4M
Year High 11.71
Year Low 5.03
Earnings Per Share -1.49
P/E Ratio -4.22
Dividend N/A
Yield N/A
Glass Door

Business Services Industry Companies

Company Employer Rating
PayPal 3.1
FedEx 3.7
Accenture 3.4
Gartner 3.3
UPS 3.1
IndustryTop Rated
advertisement
Click Here